Mirum Pharmaceuticals (MIRM) Share-based Compensation (2019 - 2026)

Mirum Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 71.7% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $60.1 million (up 13.82% YoY), while the FY2025 annual figure was $71.4 million, up 47.44% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.5 million, down from $19.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $38.8 million in Q4 2024, with the low at -$13.7 million in Q3 2024.
• The 5-year median for Share-based Compensation is $9.7 million (2023), against an average of $10.9 million.
• Peak annual rise in Share-based Compensation reached 5817.5% in 2024, while the deepest fall reached 262.81% in 2024.
• Mirum Pharmaceuticals' Share-based Compensation stood at $27.0 million in 2022, then tumbled by 64.01% to $9.7 million in 2023, then jumped by 299.29% to $38.8 million in 2024, then tumbled by 50.98% to $19.0 million in 2025, then sank by 76.5% to $4.5 million in 2026.
• Business Quant data shows MIRM's Share-based Compensation at $4.5 million in Q1 2026, $19.0 million in Q4 2025, and $18.1 million in Q3 2025.